For example, an early clinical trial of the ActRIIb ligand trap, ACE-031, in Duchenne muscular dystrophy was terminated prematurely due to epistaxis and telangiectasis26 attributed to BMP9 or BMP10 reactivity26,61. This evidence concerns the gene BMP10 and Duchenne muscular dystrophy.